What it is
Semaglutide is a glucagon-like peptide-1 (GLP-1) analogue investigated in metabolic disease. The reference here is STEP 1, a controlled study of weight management in adults with overweight or obesity without diabetes. A named molecule in a publication should not be confused with proof that any research material bearing that name has the same identity, quality, or clinical suitability.[2]
Research areas and evidence
STEP 1 randomly assigned 1,961 adults to semaglutide or placebo alongside lifestyle intervention for 68 weeks. Mean body-weight change was approximately minus 14.9% with semaglutide and minus 2.4% with placebo. This is direct human evidence for a defined trial endpoint, not a prediction for an individual. The comparison includes the trial's eligibility rules and accompanying lifestyle support; it should not be generalized to healthy people seeking performance enhancement or to every formulation.[2]
Safety and unknowns
Nausea and diarrhoea were the most common adverse events in STEP 1. Gastrointestinal events led to more treatment discontinuations in the semaglutide group than the placebo group. A trial can document common events without ruling out uncommon harms or answering every long-term question. This selected study is not a complete prescribing-safety review, and the library does not provide dose selection, administration instructions, or a basis for self-treatment. The cited results concern the studied clinical product and setting, not Atlas inventory.[2]
Sources
Read the original studies and reviews. These selected sources may not include newer research.
- Randomized human trial: STEP 1[2] Wilding et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM (2021).